Stable Angina Market

DelveInsight’s “Stable Angina – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the stable angina, historical and forecasted epidemiology as well as the stable angina market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

 

The stable angina market report provides current treatment practices, emerging drugs, stable angina market share of the individual therapies, and current and forecasted market size from 2019 to 2032, segmented by seven major markets. The report also covers current stable angina treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

 

Study period: 2019–2032

 

Stable Angina Understanding and Treatment Algorithm

The DelveInsight’s stable angina market report gives a thorough understanding of stable angina by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Angina is chest pain or discomfort occurs when required oxygen demand of the myocardium cannot be met. It is a prominent symptom of an underlying heart problem, usually coronary heart disease (CHD), or coronary artery disease (CAD). The most often types of Angina are: Stable angina also called angina pectoris, unstable angina, microvascular angina, and vasospastic or variant angina. Patients with stable angina usually know the level of activity or stress that brings on an attack. Chest pain occurs when heart is working hard enough to need more oxygen, such as during exercise. Individuals with stable angina will often have a subacute versus chronic presentation. It is important to use history and physical as a screening tool to identify high-risk individuals.

 

It has a regular pattern, and a person may experience it for months or years. Rest or medication often relieves the symptoms. Unstable angina-This is either new chest pain or a change in the usual pattern of chest pain, whether it's worsening, lasting longer, or not being relieved by rest or medication. Unstable angina is dangerous and a warning sign of a heart attack. Stable angina can turn into unstable angina. Signs of this include having chest pain at rest position, stays on for at least 15 minutes, and does not go away after take nitroglycerin. Symptoms: Angina involves sensations in the chest like squeezing, pressure, heaviness, tightening and burning or aching across the chest, usually starting behind the breastbone.

 

Stable angina diagnosis

The diagnosis of stable angina Pain is confirmed by thorough clinical history and evaluation that includes electrocardiogram, exercise stress test, coronary angiogram, Echocardiogram, Cardiac computerized tomography (CT) scan.

 

Stable angina treatment

The treatment involves clinical treatment, non-surgical procedures and surgical approach. Different drugs such as Aspirin, Clopidogrel, Metoprolol, Atenolol, Propranolol, Amlodipine, Ramipril and Ranolazine are used to reduce morbidity and to prevent complications relating to angina pectoris. Beta-adrenergic overcrowding agents, calcium channel overcrowding agents, and short and long substitute nitrates are the basis of therapeutic treatment for patients with persistent angina.

 

Stable Angina Epidemiology

The stable angina epidemiology section provides insights into historical and current stable angina patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the stable angina report also provides the diagnosed patient pool, their trends and assumptions undertaken.

 

Key findings

As per Manolis et al. (2019), prevalence of stable around 2–4% of the general population in western European countries. They conducted a patient survey in four European countries (Italy, Germany, Spain, United Kingdom [UK]). Out of more than 25,000 subjects who accessed the survey, 268 were eligible and completed the questionnaire: mean age was 61 years and women accounted for 30%. Among the final cohort of 268 patients, 17.5% were from Germany, 26.1% from Spain, 20.9% from Italy and 35.5% from the UK.

 

The stable angina epidemiology covered in the report provides historical as well as forecasted stable angina epidemiology [segmented as Total Prevalent Cases of Angina, Diagnosed Prevalent Cases of Angina, Diagnosed Prevalent Cases of Stable Angina, Gender-specific Prevalent Cases of Stable Angina, and Age-specific Prevalent Cases of Stable Angina] in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Country-wise Stable Angina Epidemiology

The epidemiology segment also provides the stable angina epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

 

Stable Angina Drug Chapters

The drug chapter segment of the stable angina report encloses the detailed analysis of stable angina marketed drugs and late-stage (Phase III and Phase II) stable angina pipeline drugs. It also helps understand the stable angina clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Stable Angina Marketed Drugs

RANEXA (ranolazine): CV Therapeutics

RANEXA (ranolazine), approved by the FDA in 2006, is a unique anti‐ischemic drug that does not significantly affect haemodynamic parameters. As an adjunct to standard doses of anti‐ischemia drugs (atenolol, amlodipine, diltiazem), ranolazine had an additional antianginal and anti‐ischemic effect, without causing significant haemodynamic changes.

Note: Detailed current therapies assessment will be provided in the full report of stable angina.

 

Stable Angina Emerging drugs

The report details the emerging stable angina therapies under the late and mid-stage of development for stable angina treatment.

 

T89: Tasly Pharmaceuticals

Tasly Pharmaceuticals, Inc. is investigating the safety and efficacy of T89 in patients with stable angina pectoris, with an extended open-label period to evaluate the long-term safety of T89. By the name DANTONIC, it is currently approved in nearly 26 countries (not in the USA yet) for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. It is coded as T89 in the US development. T89 has been studied in well controlled US and global clinical trial. It is a modernized and industrialized botanical drug formula. The outcome of the Phase III trial could lead to the first multi-herbal prescription drug to be in the North American pharmaceutical marketplace which will provide a healthier treatment option for patients with stable angina.

Note: Detailed emerging therapies assessment will be provided in the full report of stable angina.

 

Stable Angina Market Outlook

The stable angina market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Stable angina market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the stable angina market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

Key players such as Tasly Pharmaceuticals, and Arbor Pharmaceuticals along with few others are involved in developing therapies for stable angina.

 

According to DelveInsight, the stable angina market in 7MM is expected to witness a major change in the study period 2019–2032.

 

Key findings

This section includes a glimpse of the stable angina market in 7MM.

 

The United States: Stable Angina Market Outlook

This section provides the total stable angina market size and market size by therapies in the United States.

 

EU4 and the UK: Stable Angina Market Outlook

The total stable angina market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan: Stable Angina Market Outlook

The total stable angina market size and market size by therapies in Japan is also mentioned.

 

Analyst Commentary

• The pipeline of lumbosacral radicular pain is very robust, many potential therapies are being investigated for the treatment of stable angina, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the stable angina in the 7MM. Aside from that, the market size of stable angina may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of stable angina may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists

 

Stable Angina Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the stable angina market or expected to get launched in the market during the study period 2019–2032. The analysis covers stable angina market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This will help in understanding the stable angina drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

Stable Angina Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses stable angina key players involved in developing targeted therapeutics.

 

Stable Angina market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for stable angina emerging therapies.

 

Stable Angina Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the stable angina domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with stable angina market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the stable angina market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Report

• Descriptive overview of stable angina , disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the stable angina epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for stable angina, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the stable angina market; historical and forecasted covering drug outreach in the 7MM
• Trends shaping and driving the global stable angina market

 

Report Highlights

• In the coming years, the stable angina market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence stable angina R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
• Major players are involved in developing stable angina therapies. The launch of emerging therapies will significantly impact the stable angina market
• A better understanding of stable angina pathogenesis will also contribute to the development of novel therapeutics for stable angina
• Our in-depth analysis of the stable angina pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Stable angina Report Insights

• Patient population
• Therapeutic approaches
• Stable angina pipeline analysis
• Stable angina market size and trends
• Stable angina market opportunities
• Impact of upcoming therapies

 

Stable angina Report Key Strengths

• 11 years forecast
• 7MM coverage
• Stable angina epidemiology segmentation
• Key cross competition
• KOL views
• Stable angina drugs uptake

 

Stable angina Report Assessment

• Current treatment practices
• Unmet needs
• Stable angina pipeline product profiles
• Stable angina market attractiveness

 

Key Questions

Stable angina market insights:

• What would be the stable angina market growth till 2032, and what will be the resultant market size in 2032?
• What was the stable angina drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the stable angina total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest stable angina market size during the forecast period (2019–2032)
• How would the unmet needs affect the stable angina market dynamics and subsequent analysis of the associated trends?

 

Stable angina Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of stable angina?
• What is the historical and forecasted stable angina patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Stable angina in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to stable angina therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for stable angina and its status, along with the challenges faced?

 

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the stable angina market
• Organize sales and marketing efforts by identifying the best opportunities for stable angina in the US, EU4 (Germany, France, Italy, Spain) and the UK, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors